Shanghai Junshi Biosciences Co., Ltd. (SHJBF) Prévision du cours des actions

Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 2,903 full-time employees. The company went IPO on 2018-12-24. Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The firm primarily operates its businesses in the domestic and American markets.